Minimal residual disease is a sensitive way to measure disease ... Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.

Residual disease can now be tracked in hematological malignancies, including leukemia, lymphoma and myeloma, and the benefits of these MRD tests have grown in tandem with their sensitivity and ...

The goal of myeloma therapy is personalized medicine, whereby biomarkers are used to define a patient group that will derive benefit from a specific drug. This approach is being driven by two main ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...

Multiple myeloma is the second most common form of hematological (blood) cancer with over 175,000 new cases diagnosed each year worldwide. The detection of MRD in patients with MM serves as one of ...

is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Tel ...

is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Tel ...

Chief Executive Officer of Legend Biotech. “MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. The significantly increased overall and ...